阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化的疗效观察

Efficacy of adefovir dipivoxil combined with lamivudine on patients with hepatitis B related liver cirrhosis

目的研究阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化的疗效。方法将52例存在HBV复制的失代偿期肝硬化患者,随机均分为阿德福韦酯联合拉米夫定治疗组(观察组)和对照组,对照组单用阿德福韦酯治疗,分别治疗12、24和36个月后比较疗效。结果治疗后两组患者HBVDNA载量均较治疗前显著下降;但观察组较对照组下降更为明显,差异具有统计学意义(P<0.05)。治疗36个月时,观察组患者临床有效率显著优于对照组(P<0.05)。结论阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化的疗效确切,可快速抑制病毒复制和改善肝功能,是一种较好的乙型肝炎肝硬化的治疗方法。

Objective To investigate the efficacy of adefovir dipivoxil combined with lamivudine on patients with hepatitis B related liver cirrhosis. Methods Total of 52 cases with decompensated liver cirrhosis with HBV duplication were divided into two groups, randomly. The observation group was given adefovir dipivoxil combined with lamivudine and the control group was given adefovir dipivoxil only. Both groups were treated for 12, 24 and 36 months, and the efficacy were compared. Results HBV DNA levels of patients in both groups after treatment decreased significantly compared with before treatment; but the effective rate of the observation group decreased more significantly than the control group, with significant difference （P 〈 0.05）. After treated for 36 months, the effective rate of patients in the observation group was significantly higher than the control group （ P 〈 0.05 ）. Conclusions The efficacy of adefovir dipivoxil combined with lamivudine on hepatitis B related liver cirrhosis is effective, which could significantly improve the liver function and reduced HBV DNA level, and is a good treatment method for hepatitis B related liver cirrhosis.